XCEL-MC-ALPHA ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02495766 (ClinicalTrials.gov)	May 11, 2015	3/6/2015	Autologous Mesenchymal Stromal Cells for Multiple Sclerosis	Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: XCEL-MC-ALPHA;Drug: Placebo	Banc de Sang i Teixits	Vall d'Hebron Research Institute (VHIR)	Completed	18 Years	60 Years	All	8	Phase 1/Phase 2	Spain
2	EUCTR2012-000734-19-ES (EUCTR)	10/04/2014	10/01/2014	Bone marrow cell treatment as treatment of multiple sclerosis	Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES	Multiple Sclerosis MedDRA version: 16.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: XCEL-MC-ALPHA Product Code: XCEL-MC-ALPHA INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved Other descriptive name: Mesenchymal Stem Cells	Banc de Sang i Teixits	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Spain